Compare Stocks

Date Range: 

 Harmony BiosciencesAurinia PharmaceuticalsHeron TherapeuticsuniQureMyovant Sciences
SymbolNASDAQ:HRMYNASDAQ:AUPHNASDAQ:HRTXNASDAQ:QURENYSE:MYOV
Price Information
Current Price$27.55$12.27$16.84$30.48$19.51
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.41.51.71.71.3
Analysis Score3.53.43.43.53.3
Community Score2.13.02.72.92.6
Dividend Score0.00.00.00.00.0
Ownership Score0.80.81.71.70.0
Earnings & Valuation Score0.60.00.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$51.67$28.50$26.00$68.46$32.17
% Upside from Price Target87.54% upside132.27% upside54.39% upside124.61% upside64.87% upside
Trade Information
Market Cap$1.60 billion$1.56 billion$1.54 billion$1.39 billion$1.82 billion
BetaN/A0.871.521.192.99
Average Volume125,2884,179,6181,024,973469,384909,442
Sales & Book Value
Annual RevenueN/A$320,000.00$145.97 million$7.28 millionN/A
Price / SalesN/A4,912.6410.58188.38N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/A$2.45 per share$4.48 per share$7.41 per share($1.21) per share
Price / BookN/A5.013.764.11N/A
Profitability
Net IncomeN/A$-123,850,000.00$-204,750,000.00$-124,200,000.00$-288,990,000.00
EPSN/A($0.89)($2.50)($3.11)($3.37)
Trailing P/E Ratio0.00N/AN/AN/AN/A
Forward P/E Ratio23.75N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-173,992.23%-216.18%-2,738.33%N/A
Return on Equity (ROE)N/A-36.98%-65.06%-59.64%N/A
Return on Assets (ROA)N/A-31.06%-49.14%-41.47%-201.20%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio2.04%N/AN/A0.16%N/A
Current Ratio7.87%17.23%3.60%8.62%1.75%
Quick Ratio7.80%16.95%3.16%8.62%1.75%
Ownership Information
Institutional Ownership Percentage50.17%51.21%99.01%78.34%33.77%
Insider Ownership PercentageN/AN/A12.85%2.79%3.90%
Miscellaneous
Employees150294223332214
Shares Outstanding56.89 million128.12 million91.68 million44.99 million90.80 million
Next Earnings Date5/11/2021 (Confirmed)5/6/2021 (Confirmed)5/5/2021 (Estimated)5/5/2021 (Estimated)5/11/2021 (Confirmed)
OptionableNot OptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Myovant Sciences (MYOV) Set to Announce Earnings on TuesdayMyovant Sciences (MYOV) Set to Announce Earnings on Tuesday
americanbankingnews.com - May 5 at 11:30 AM
Pfizer (PFE) Q1 2021 Earnings Call TranscriptPfizer (PFE) Q1 2021 Earnings Call Transcript
msn.com - May 5 at 12:28 AM
Myovant Sciences Ltd. (NYSE:MYOV) Given Average Rating of "Hold" by BrokeragesMyovant Sciences Ltd. (NYSE:MYOV) Given Average Rating of "Hold" by Brokerages
americanbankingnews.com - May 4 at 2:44 PM
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
finance.yahoo.com - May 4 at 9:24 AM
Roivant and Montes Archimedes Merge in Cash-Rich SPACRoivant and Montes Archimedes Merge in Cash-Rich SPAC
pharmalive.com - May 3 at 12:35 PM
JPMorgan Chase & Co. Cuts Myovant Sciences (NYSE:MYOV) Price Target to $32.00JPMorgan Chase & Co. Cuts Myovant Sciences (NYSE:MYOV) Price Target to $32.00
americanbankingnews.com - May 3 at 8:04 AM
Myovant Sciences Ltd. (NYSE:MYOV) Sees Large Decrease in Short InterestMyovant Sciences Ltd. (NYSE:MYOV) Sees Large Decrease in Short Interest
americanbankingnews.com - May 3 at 7:24 AM
Argos Therapeutics (OTCMKTS:ARGSQ) vs. Myovant Sciences (NYSE:MYOV) Critical ContrastArgos Therapeutics (OTCMKTS:ARGSQ) vs. Myovant Sciences (NYSE:MYOV) Critical Contrast
americanbankingnews.com - April 27 at 8:16 PM
Myovant Sciences Breaks Above 200-Day Moving Average - Bullish for MYOVMyovant Sciences Breaks Above 200-Day Moving Average - Bullish for MYOV
nasdaq.com - April 26 at 7:31 PM
40 Under 40 Class of 2021: Jarrad Aguirre, Myovant Sciences40 Under 40 Class of 2021: Jarrad Aguirre, Myovant Sciences
bizjournals.com - April 23 at 10:14 AM
Myovant Sciences Ltd. (NYSE:MYOV) Expected to Announce Earnings of -$0.88 Per ShareMyovant Sciences Ltd. (NYSE:MYOV) Expected to Announce Earnings of -$0.88 Per Share
americanbankingnews.com - April 21 at 12:18 PM
Zacks Investment Research Lowers Myovant Sciences (NYSE:MYOV) to SellZacks Investment Research Lowers Myovant Sciences (NYSE:MYOV) to Sell
marketbeat.com - April 21 at 2:20 AM
First Week of June 18th Options Trading For Myovant Sciences (MYOV)First Week of June 18th Options Trading For Myovant Sciences (MYOV)
nasdaq.com - April 16 at 5:41 PM
Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo StudyMyovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
finance.yahoo.com - April 13 at 6:04 PM
Myovant, Pfizer Initiate SERENE Study Evaluating Contraceptive Efficacy Of RelugolixMyovant, Pfizer Initiate SERENE Study Evaluating Contraceptive Efficacy Of Relugolix
nasdaq.com - April 12 at 2:32 PM
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-DailyMyovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily
miragenews.com - April 12 at 9:32 AM
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive BladderUrovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
ca.finance.yahoo.com - April 12 at 9:32 AM
BRIEF-Myovant Sciences And Pfizer Announce First Participant Dosed In Phase 3 Serene Study Evaluating Contraceptive Efficacy Of Once-Daily Relugolix Combination TabletBRIEF-Myovant Sciences And Pfizer Announce First Participant Dosed In Phase 3 Serene Study Evaluating Contraceptive Efficacy Of Once-Daily Relugolix Combination Tablet
msn.com - April 12 at 9:32 AM
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating ...Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating ...
apnews.com - April 12 at 9:32 AM
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination TabletMyovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
finance.yahoo.com - April 12 at 9:32 AM
RSI Alert: Myovant Sciences (MYOV) Now OversoldRSI Alert: Myovant Sciences (MYOV) Now Oversold
nasdaq.com - April 7 at 6:22 PM
Myovant Sciences (MYOV) Shares Cross Below 200 DMAMyovant Sciences (MYOV) Shares Cross Below 200 DMA
nasdaq.com - April 5 at 12:56 PM
Myovant Sciences Appoints Lauren Merendino as Chief Commercial OfficerMyovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
finance.yahoo.com - April 5 at 7:43 AM
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization ...Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization ...
apnews.com - March 30 at 7:37 AM
Myovant Sciences: EMA to Review Relugolix for Advanced Prostate CancerMyovant Sciences: EMA to Review Relugolix for Advanced Prostate Cancer
morningstar.com - March 29 at 9:45 AM
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate CancerMyovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
finance.yahoo.com - March 29 at 9:44 AM
DateCompanyBrokerageAction
3/29/2021Harmony BiosciencesThe Goldman Sachs GroupUpgrade
9/14/2020Harmony BiosciencesJefferies Financial GroupInitiated Coverage
9/14/2020Harmony BiosciencesPiper SandlerInitiated Coverage
4/11/2021Aurinia PharmaceuticalsSVB LeerinkReiterated Rating
2/25/2021Aurinia PharmaceuticalsRoyal Bank of CanadaLower Price Target
1/26/2021Aurinia PharmaceuticalsCantor FitzgeraldBoost Price Target
1/25/2021Aurinia PharmaceuticalsOppenheimerBoost Price Target
1/25/2021Aurinia PharmaceuticalsHC WainwrightBoost Price Target
11/3/2020Aurinia PharmaceuticalsBloom BurtonDowngrade
6/16/2020Aurinia PharmaceuticalsBTIG ResearchInitiated Coverage
5/5/2020Aurinia PharmaceuticalsCowenInitiated Coverage
9/8/2020Heron TherapeuticsStifel NicolausReiterated Rating
8/6/2020Heron TherapeuticsNorthland SecuritiesInitiated Coverage
5/26/2020Heron TherapeuticsGuggenheimInitiated Coverage
5/18/2020Heron TherapeuticsFIXInitiated Coverage
4/15/2020Heron TherapeuticsNeedham & Company LLCReiterated Rating
10/3/2019Heron TherapeuticsJMP SecuritiesLower Price Target
8/13/2019Heron TherapeuticsEvercore ISIReiterated Rating
4/1/2021uniQureMizuhoUpgrade
3/8/2021uniQureChardan CapitalBoost Price Target
11/20/2020uniQureCredit Suisse GroupBoost Price Target
11/11/2020uniQureBerenberg BankInitiated Coverage
8/24/2020uniQureRaymond JamesInitiated Coverage
7/31/2020uniQureRobert W. BairdUpgrade
5/3/2021Myovant SciencesJPMorgan Chase & Co.Lower Price Target
6/2/2020Myovant SciencesCitigroupBoost Price Target
2/13/2019Myovant SciencesBarclaysUpgrade
(Data available from 5/5/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.